Novavax Appoints Stanley Erck to Board of Directors

ROCKVILLE, Md., June 26 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX)
announced today the appointment of Stanley Erck to the company's Board of
Directors. Mr. Erck has more than twenty five years of experience in the
biotechnology and health-care industries and served most recently as President
and Chief Executive Officer of Iomai Corporation, a developer of vaccines and
immune system therapies that was acquired in 2008 by Intercell. Previously,
Mr. Erck was President and Chief Executive Officer of Procept, a publicly
traded immunology company, Vice President of Corporate Development at
Integrated Genetics (now Genzyme), and in management positions at Baxter
International. His appointment brings the number of Novavax board members to
nine.

John Lambert, Chairman of the Board of Novavax, stated: "We are pleased to
have Stanley Erck join our board and bring his pharmaceutical knowledge and
many years of experience in vaccine development to our company. He has a
strong record of achievement in building successful companies, a keen
understanding of the market for infectious disease products and valuable
experience in working with public health agencies. We welcome his anticipated
contributions to our future success as we expand our pipeline of promising
vaccine candidates."

Mr. Erck is also a Director of BioCryst Pharmaceuticals, MaxCyte, Inc. and
MdBio Foundation. He received his undergraduate degree from the University of
Illinois and his masters in business administration from the University of
Chicago.

ABOUT NOVAVAX
Novavax, Inc. (Nasdaq: NVAX) is a clinical-stage biotechnology company
creating novel vaccines, including H1N1, to address a broad range of
infectious diseases worldwide using advanced proprietary virus-like-particle
(VLP) technology. The company produces these VLP-based, potent, recombinant
vaccines utilizing new and efficient manufacturing approaches. Additional
information about Novavax is available at www.novavax.com and in the company's
various filings with the Securities and Exchange Commission.

Forward Looking Statement
Statements herein relating to future financial or business performance,
conditions or strategies and other financial and business matters, including
expectations regarding revenues, operating expenses, cash burn, and clinical
developments and anticipated milestones are forward-looking statements within
the meaning of the Private Securities Litigation Reform Act. Novavax cautions
that these forward-looking statements are subject to numerous assumptions,
risks and uncertainties, which change over time. Factors that may cause actual
results to differ materially from the results discussed in the forward-looking
statements or historical experience include risks and uncertainties, including
the Company's ability to progress any product candidates in preclinical or
clinical trials; the scope, rate and progress of its preclinical studies and
clinical trials and other research and development activities; clinical trial
results; current results may not be predictive of future results; even if the
data from preclinical studies or clinical trials is positive, the product may
not prove to be safe and efficacious; Novavax's pilot plant facility is
subject to extensive validation and FDA inspections, which may result in
delays and increased costs; our ability to enter into future collaborations
with industry partners and the government and the terms, timing and success
of any such collaboration; the cost of filing, prosecuting, defending and
enforcing any patent claims and other intellectual property rights; our
ability to obtain rights to technology; competition for clinical resources and
patient enrollment from drug candidates in development by other companies with
greater resources and visibility; our ability to obtain adequate financing in
the future through product licensing, co-promotional arrangements, public or
private equity or debt financing or otherwise; the maturity of the
convertible notes on July 15, 2009; general business conditions; competition;
business abilities and judgment of personnel; and the availability of
qualified personnel. Further information on the factors and risks that could
affect Novavax's business, financial conditions and results of operations, is
contained in Novavax's filings with the U.S. Securities and Exchange
Commission, which are available at www.sec.gov. These forward-looking
statements speak only as of the date of this press release, and Novavax
assumes no duty to update forward-looking statements.

SOURCE Novavax, Inc.

Tricia J. Richardson, Novavax, Inc., +1-240-268-2031